These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 1037379)
21. Role of ergot derivatives in the treatment of parkinsonism. Calne DB Fed Proc; 1978 Jun; 37(8):2207-9. PubMed ID: 658459 [No Abstract] [Full Text] [Related]
22. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients. Schneider E; Hubener K; Fischer PA Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631 [No Abstract] [Full Text] [Related]
24. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor]. Meco G; Casacchia M; Zamponi A; Agnoli A Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427 [No Abstract] [Full Text] [Related]
25. [Therapy of acromegaly using bromocriptine]. Köbberling J; Schwinn G; Dirks H Dtsch Med Wochenschr; 1975 Jul; 100(29):1540-2. PubMed ID: 1149634 [TBL] [Abstract][Full Text] [Related]
26. Bromocriptine and endocrine imbalance. Hopkins S Nurs Mirror; 1981 Mar; 152(12):38. PubMed ID: 6908001 [No Abstract] [Full Text] [Related]
27. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies. LeWitt PA; Burns RS; Calne DB Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586 [TBL] [Abstract][Full Text] [Related]
28. Letter: Bromocriptine and growth hormone. Morgan L; Barrett A; Hobbs JR Lancet; 1976 Jan; 1(7952):195. PubMed ID: 54704 [No Abstract] [Full Text] [Related]
29. [Crises in the course of Parkinson's disease]. Danielczyk W Wien Med Wochenschr; 1980 Feb; 130(4):149-51. PubMed ID: 7376682 [No Abstract] [Full Text] [Related]
30. [Neuroleptic malignant syndrome. Efficacy of bromocriptine]. Azorin JM; Bouchacourt M; Lavergne T; Giudicelli S Presse Med; 1984 Jun; 13(27):1702. PubMed ID: 6146134 [No Abstract] [Full Text] [Related]
32. Progress in the pharmacotherapy of Parkinsonism. Calne DB; Eisler T; Gopinathan G; Williams A Adv Biochem Psychopharmacol; 1980; 23():237-43. PubMed ID: 6104907 [No Abstract] [Full Text] [Related]
33. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782 [TBL] [Abstract][Full Text] [Related]
34. Pergolide in late-stage Parkinson disease. Lang AE; Quinn N; Brincat S; Marsden CD; Parkes JD Ann Neurol; 1982 Sep; 12(3):243-7. PubMed ID: 6753730 [TBL] [Abstract][Full Text] [Related]
35. Low-dose bromocriptine in the early phases of Parkinson's disease. Tolosa E; Blesa R; Bayes A; Forcadell F Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610 [TBL] [Abstract][Full Text] [Related]
36. MPTP toxicity: clinical features. Williams A J Neural Transm Suppl; 1986; 20():5-9. PubMed ID: 3489070 [TBL] [Abstract][Full Text] [Related]
37. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride. Stracke H; Heinlein W; Horowski R; Schatz H Arzneimittelforschung; 1986 Dec; 36(12):1834-6. PubMed ID: 3566845 [TBL] [Abstract][Full Text] [Related]
38. Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism. Gomez-Mancilla B; Boucher R; Bédard PJ Mov Disord; 1992; 7(1):43-7. PubMed ID: 1348351 [TBL] [Abstract][Full Text] [Related]
39. Current concepts in drug therapy. (21) Bromocriptine "Parlodel" (Sandoz). Lionel ND Ceylon Med J; 1976 Jun; 21(2):152-5. PubMed ID: 1037381 [No Abstract] [Full Text] [Related]